SCHEMBL7625720

SCHEMBL7625720

Nc1ncnc2c1ncn2[C@]1(C(F)(F)F)O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 5/20 0.51
ADORA2A P29274 3/20 0.51
SLC28A1 O00337 2/20 0.51
PI4KA P42356 2/20 0.51
PI4K2B Q8TCG2 2/20 0.51
PI4K2A Q9BTU6 2/20 0.51
PI4KB Q9UBF8 2/20 0.51
DPP4 P27487 1/20 0.51
MEN1 O00255 1/20 0.51
MAP3K7 O43318 1/20 0.51
SLC28A2 O43868 1/20 0.51
GAPDH P04406 1/20 0.51
MAPK1 P28482 1/20 0.51
ADORA2B P29275 1/20 0.51
ADORA1 P30542 1/20 0.51
STAT6 P42226 1/20 0.51
KMT2A Q03164 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
DOT1L Q8TEK3 1/20 0.51
SLC29A1 Q99808 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphoric Acid SCHEMBL21465204 0.95 ADORA1 (0.48) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL10605530 0.87 PI4KA (0.48) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL9705275 0.85 ADORA3 (0.46) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL5181193 0.85 ADORA3 (0.48) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL29457186 0.84 ADORA3 (0.53) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL29464979 0.84 ADORA3 (0.53) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL2120940 0.84 ADORA3 (0.53) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL674400 0.84 ADORA1 (0.48) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL6852710 0.84 ADORA1 (0.48) ADORA3ADORA2ASLC28A1PI4KAPI4K2B
SCHEMBL481525 0.83 ADORA3 (0.55) ADORA3ADORA2ASLC28A1PI4KAPI4K2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025125630-A1 METHOD FOR BIOPROTAC DESIGN MEDIMMUNE LIMITED (GB) 2025-06-19 WO disclosed
WO-2024151673-A2 RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-07-18 WO disclosed
WO-2024151687-A1 GENETIC SWITCHES AND THEIR USE IN TREATING CANCER FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2024-07-18 WO disclosed
WO-2024151685-A1 RECOMBINANT NUCLEIC ACID MOLECULES AND THEIR USE IN WOUND HEALING BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) 2024-07-18 WO disclosed
WO-2024133160-A1 HEPATITIS B COMPOSITIONS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-06-27 WO disclosed
EP-4387596-A1 LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME GlaxoSmithKline Biologicals SA (BE) 2024-06-26 EP disclosed
EP-4387597-A1 FREEZE-DRYING OF LIPID NANOPARTICLES (LNPS) ENCAPSULATING RNA AND FORMULATIONS THEREOF GlaxoSmithKline Biologicals SA (BE) 2024-06-26 EP disclosed
WO-2024113009-A1 AGENTS, COMPOSITIONS AND METHODS FOR MODULATING IMMUNITY THE UNIVERSITY OF QUEENSLAND (AU) 2024-06-06 WO disclosed
WO-2024077191-A1 NUCLEIC ACID MOLECULES ENCODING TRIF AND ADDITIONALPOLYPEPTIDES AND THEIR USE IN TREATING CANCER FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2024-04-11 WO disclosed
WO-2024064965-A2 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF ADVANCED RNA VACCINE (ARV) TECHNOLOGIES, INC. (US) 2024-03-28 WO disclosed
WO-2017070622-A1 RESPIRATORY SYNCYTIAL VIRUS VACCINE MODERNATX, INC. (US) 2017-04-27 WO disclosed
WO-2017015457-A1 EBOLA VACCINE MODERNATX, INC. (US) 2017-01-26 WO disclosed
WO-2017011773-A2 CODON-OPTIMIZED NUCLEIC ACIDS ENCODING ANTIBODIES MODERNATX, INC. (US) 2017-01-19 WO disclosed
WO-2016100812-A1 TERMINAL MODIFICATIONS OF POLYNUCLEOTIDES MODERNA THERAPEUTICS, INC. (US) 2016-06-23 WO disclosed
WO-2016077123-A1 MULTIPARAMETRIC NUCLEIC ACID OPTIMIZATION MODERNA THERAPEUTICS, INC. (US) 2016-05-19 WO disclosed
WO-2016014846-A1 MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF INTRABODIES MODERNA THERAPEUTICS, INC. (US) 2016-01-28 WO disclosed
EP-1248632-A2 COMBINATIONS OF AN ADENOSINE A1 AGONIST WITH AN OPIOID AND THEIR USE IN THE TREATMENT OF PAIN GLAXO GROUP LIMITED (GB) 2002-10-16 EP disclosed
EP-1239878-A2 FORMULATIONS OF ADENOSINE A1 AGONISTS GLAXO GROUP LIMITED (GB) 2002-09-18 EP disclosed
WO-2001045682-A2 FORMULATIONS OF ADENOSINE A1 AGONISTS GLAXO GROUP LIMITED (GB) 2001-06-28 WO disclosed
WO-2001045715-A2 COMBINATIONS OF AN ADENOSINE A1 AGONIST WITH AN OPIOID AND THEIR USE IN THE TREATMENT OF PAIN GLAXO GROUP LIMITED (GB) 2001-06-28 WO disclosed